Radiation, Chemotherapy, Vaccine and Anti-MART-1 and Anti-gp100 Cells for Patients With Metastatic Melanoma

NCT00923195 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

4

Enrollment

NIH

Sponsor class

Conditions

Melanoma
Skin Cancer

Interventions

DRUG: MART-1: 26-35(27L) Peptide
DRUG: Montanide ISA 51 VG
DRUG: gp100:154-162 Peptide
PROCEDURE: Radiation
DRUG: Aldesleukin
DRUG: Fludarabine
DRUG: Cyclophosphamide
GENETIC: Anti-gp 100:154 TCR PBL
GENETIC: Anti-MART-1 F5 TCR PBL

Sponsor

National Cancer Institute (NCI)